DOAC

ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3:29
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes,

Watch time: 3:57
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly,

Watch time: 4:59
ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s
View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24:27

Payam Pournazari , Su Min Chang , Stephen H Little , et al

ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

HRS 21: Results from the STROKE-VT Trial

Dhanunjaya Lakkireddy,

TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

ESC 2020: Edoxaban for Elderly AF Patients — Dr Ken Okumura

Ken Okumura,

HRS 2020: Incidence of Silent Brain Infarcts in Anticoagulated Patients with AF

Alex Spyropoulos, Gary E Raskob,

View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24:27

Payam Pournazari , Su Min Chang , Stephen H Little , et al

Philip J Devereaux, John Eikelboom,

ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

HRS 21: Results from the STROKE-VT Trial

Dhanunjaya Lakkireddy,

ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3:29
RC Live Stream: The MANAGE Late Breaking Trial - ACC 2018

Philip J Devereaux, John Eikelboom,

Dual Antithrombotic Therapy With Dabigatran

Christopher P Cannon,

ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

ESC 2020: Edoxaban for Elderly AF Patients — Dr Ken Okumura

Ken Okumura,

Media

ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3:29
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes,

Watch time: 3:57
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly,

Watch time: 4:59
ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s
View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24:27
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

HRS 21: Results from the STROKE-VT Trial

Dhanunjaya Lakkireddy,

TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

ESC 2020: Edoxaban for Elderly AF Patients — Dr Ken Okumura

Ken Okumura,

HRS 2020: Incidence of Silent Brain Infarcts in Anticoagulated Patients with AF

AHA 2019: Updates from GALILEO-4D

Ole De Backer,

AHA 2019: Clinical Data Update on TWILIGHT and TWILIGHT-ACS

Marc P Bonaca, Roxana Mehran,

Alex Spyropoulos, Gary E Raskob,

RC Live Stream: The MANAGE Late Breaking Trial - ACC 2018

Philip J Devereaux, John Eikelboom,

Philip J Devereaux, John Eikelboom,

Dual Antithrombotic Therapy With Dabigatran

Christopher P Cannon,

Articles

Prosthetic Aortic Valve Thrombosis

Payam Pournazari

,

Su Min Chang

,

Stephen H Little

,

Sachin Goel

,

Nadeen N Faza

,

Published:

08 July 2022

Citation:

US Cardiology Review 2022;16:e17.

DOI:

https://doi.org/10.15420/usc.2021.19
  • Views: Views 1074
  • Downloads: Downloads 115